Hvid-Jensen F - Search Results

1

Incidence of adenocarcinoma among patients with Barrett's esophagus.

Hvid-Jensen F, Pedersen L, Drewes AM, Sørensen HT, Funch-Jensen P. Hvid-Jensen F, et al. N Engl J Med. 2011 Oct 13;365(15):1375-83. doi: 10.1056/NEJMoa1103042. N Engl J Med. 2011. PMID: 21995385 Free article.

2

Benign and precursor lesions in the esophagus.

Akiyama J, Bertelé A, Brock C, Hvid-Jensen F, Ichiya T, Krarup AL, Majewski M, Rubio CA, Sarosiek J, Scarpignato C, Schmidt PT, Teich S, Triadafilopoulos G, Wallner G. Akiyama J, et al. Among authors: hvid jensen f. Ann N Y Acad Sci. 2014 Sep;1325:226-41. doi: 10.1111/nyas.12534. Ann N Y Acad Sci. 2014. PMID: 25266028

3

Letter: proton pump inhibitor usage still seems to reduce the risk of high-grade dysplasia and/or oesophageal adenocarcinoma in Barrett's oesophagus--authors' reply.

Hvid-Jensen F, Drewes AM, Funch-Jensen P. Hvid-Jensen F, et al. Aliment Pharmacol Ther. 2014 Oct;40(7):860-1. doi: 10.1111/apt.12931. Aliment Pharmacol Ther. 2014. PMID: 25185739 Free article. No abstract available.

4

Letter: proton pump inhibitors, GERD and oesophageal adenocarcinoma - authors' reply.

Hvid-Jensen F, Funch-Jensen P, Drewes AM. Hvid-Jensen F, et al. Aliment Pharmacol Ther. 2014 Aug;40(3):320. doi: 10.1111/apt.12847. Aliment Pharmacol Ther. 2014. PMID: 25040747 Free article. No abstract available.

5

Proton pump inhibitor use may not prevent high-grade dysplasia and oesophageal adenocarcinoma in Barrett's oesophagus: a nationwide study of 9883 patients.

Hvid-Jensen F, Pedersen L, Funch-Jensen P, Drewes AM. Hvid-Jensen F, et al. Aliment Pharmacol Ther. 2014 May;39(9):984-91. doi: 10.1111/apt.12693. Epub 2014 Mar 11. Aliment Pharmacol Ther. 2014. PMID: 24617286 Free article.

6

Lifestyle factors among proton pump inhibitor users and nonusers: a cross-sectional study in a population-based setting.

Hvid-Jensen F, Nielsen RB, Pedersen L, Funch-Jensen P, Drewes AM, Larsen FB, Thomsen RW. Hvid-Jensen F, et al. Clin Epidemiol. 2013 Dec 4;5:493-9. doi: 10.2147/CLEP.S49354. eCollection 2013. Clin Epidemiol. 2013. PMID: 24348070 Free PMC article.

7

Randomized clinical trial: inhibition of the TRPV1 system in patients with nonerosive gastroesophageal reflux disease and a partial response to PPI treatment is not associated with analgesia to esophageal experimental pain.

Krarup AL, Ny L, Gunnarsson J, Hvid-Jensen F, Zetterstrand S, Simrén M, Funch-Jensen P, Hansen MB, Drewes AM. Krarup AL, et al. Among authors: hvid jensen f. Scand J Gastroenterol. 2013 Mar;48(3):274-84. doi: 10.3109/00365521.2012.758769. Epub 2013 Jan 16. Scand J Gastroenterol. 2013. PMID: 23320520 Clinical Trial.

8

Long-term complications to reflux disease in community practice. A 17-year cohort study of 4706 patients.

Hvid-Jensen F, Pedersen L, Munk EM, Drewes AM, Funch-Jensen P. Hvid-Jensen F, et al. Scand J Gastroenterol. 2011 Oct;46(10):1179-86. doi: 10.3109/00365521.2011.594084. Epub 2011 Jul 27. Scand J Gastroenterol. 2011. PMID: 21793632

9

Barrett's oesophagus: size does matter.

de Jonge PJ, Hvid-Jensen F. de Jonge PJ, et al. Among authors: hvid jensen f. Gut. 2016 Feb;65(2):189-90. doi: 10.1136/gutjnl-2015-310091. Epub 2015 Aug 5. Gut. 2016. PMID: 26246246 No abstract available.

10

Should aspirin and PPIs be recommended for patients with Barrett's oesophagus?

Hvid-Jensen F, Drewes AM. Hvid-Jensen F, et al. Lancet. 2018 Aug 4;392(10145):362-364. doi: 10.1016/S0140-6736(18)31618-0. Epub 2018 Jul 26. Lancet. 2018. PMID: 30057101 Free article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results